Literature DB >> 20202930

Mapping of domains on HIV envelope protein mediating association with calnexin and protein-disulfide isomerase.

Marie-Jeanne Papandréou1, Rym Barbouche, Régis Guieu, Santiago Rivera, Jacques Fantini, Michel Khrestchatisky, Ian M Jones, Emmanuel Fenouillet.   

Abstract

The cell catalysts calnexin (CNX) and protein-disulfide isomerase (PDI) cooperate in establishing the disulfide bonding of the HIV envelope (Env) glycoprotein. Following HIV binding to lymphocytes, cell-surface PDI also reduces Env to induce the fusogenic conformation. We sought to define the contact points between Env and these catalysts to illustrate their potential as therapeutic targets. In lysates of Env-expressing cells, 15% of the gp160 precursor, but not gp120, coprecipitated with CNX, whereas only 0.25% of gp160 and gp120 coprecipitated with PDI. Under in vitro conditions, which mimic the Env/PDI interaction during virus/cell contact, PDI readily associated with Env. The domains of Env interacting in cellulo with CNX or in vitro with PDI were then determined using anti-Env antibodies whose binding site was occluded by CNX or PDI. Antibodies against domains V1/V2, C2, and the C terminus of V3 did not bind CNX-associated Env, whereas those against C1, V1/V2, and the CD4-binding domain did not react with PDI-associated Env. In addition, a mixture of the latter antibodies interfered with PDI-mediated Env reduction. Thus, Env interacts with intracellular CNX and extracellular PDI via discrete, largely nonoverlapping, regions. The sites of interaction explain the mode of action of compounds that target these two catalysts and may enable the design of further new competitive agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202930      PMCID: PMC2859542          DOI: 10.1074/jbc.M109.066670

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Transfer of endoplasmic reticulum and Golgi retention signals to human immunodeficiency virus type 1 gp160 inhibits intracellular transport and proteolytic processing of viral glycoprotein but does not influence the cellular site of virus particle budding.

Authors:  T Pfeiffer; H Zentgraf; B Freyaldenhoven; V Bosch
Journal:  J Gen Virol       Date:  1997-07       Impact factor: 3.891

Review 2.  The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection.

Authors:  C C Rider
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

3.  Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies.

Authors:  D H Jones; B W McBride; M A Roff; G H Farrar
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

4.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates.

Authors:  A Otteken; P L Earl; B Moss
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.

Authors:  J P Moore; Q J Sattentau; H Yoshiyama; M Thali; M Charles; N Sullivan; S W Poon; M S Fung; F Traincard; M Pinkus
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

8.  Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin.

Authors:  A Otteken; B Moss
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

9.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions.

Authors:  M J Papandreou; T Idziorek; R Miquelis; E Fenouillet
Journal:  FEBS Lett       Date:  1996-01-29       Impact factor: 4.124

View more
  9 in total

1.  Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry.

Authors:  Shuguang Bi; Patrick W Hong; Benhur Lee; Linda G Baum
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

2.  Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection.

Authors:  Shokrollah Elahi; Toshiro Niki; Mitsuomi Hirashima; Helen Horton
Journal:  Blood       Date:  2012-03-21       Impact factor: 22.113

3.  Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection.

Authors:  Tzanko S Stantchev; Mark Paciga; Carla R Lankford; Franziska Schwartzkopff; Christopher C Broder; Kathleen A Clouse
Journal:  Retrovirology       Date:  2012-12-03       Impact factor: 4.602

4.  Proteomic analysis of saliva in HIV-positive heroin addicts reveals proteins correlated with cognition.

Authors:  Stephen S Dominy; Joseph N Brown; Mark I Ryder; Marina Gritsenko; Jon M Jacobs; Richard D Smith
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

Review 5.  Immunoregulation through membrane proteins modified by reducing conditions induced by immune reactions.

Authors:  Monika Stegmann; Clive Metcalfe; A Neil Barclay
Journal:  Eur J Immunol       Date:  2013-01       Impact factor: 5.532

Review 6.  Viral and Host Factors Regulating HIV-1 Envelope Protein Trafficking and Particle Incorporation.

Authors:  Boris Anokhin; Paul Spearman
Journal:  Viruses       Date:  2022-08-05       Impact factor: 5.818

7.  HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin.

Authors:  Lucas Jennelle; Ruth Hunegnaw; Larisa Dubrovsky; Tatiana Pushkarsky; Michael L Fitzgerald; Dmitri Sviridov; Anastas Popratiloff; Beda Brichacek; Michael Bukrinsky
Journal:  J Biol Chem       Date:  2014-08-28       Impact factor: 5.157

8.  N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants.

Authors:  Yun-Ji Shin; Julia König-Beihammer; Ulrike Vavra; Jennifer Schwestka; Nikolaus F Kienzl; Miriam Klausberger; Elisabeth Laurent; Clemens Grünwald-Gruber; Klemens Vierlinger; Manuela Hofner; Emmanuel Margolin; Andreas Weinhäusel; Eva Stöger; Lukas Mach; Richard Strasser
Journal:  Front Plant Sci       Date:  2021-06-15       Impact factor: 6.627

9.  OX133, a monoclonal antibody recognizing protein-bound N-ethylmaleimide for the identification of reduced disulfide bonds in proteins.

Authors:  Lisa-Marie Holbrook; Lai-Shan Kwong; Clive L Metcalfe; Emmanuel Fenouillet; Ian M Jones; A Neil Barclay
Journal:  MAbs       Date:  2016-03-17       Impact factor: 5.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.